



Announcement Summary

Entity name
NEUROTECH INTERNATIONAL LIMITED

Date of this announcement
Thursday March 10, 2022

The +securities the subject of this notification are:
☒ Other

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
New class - code to be confirmed	Unlisted Options (\$0.08, 10 March 2024)	5,000,000	10/03/2022
New class - code to be confirmed	Unlisted Options (\$0.12, 10 March 2024)	5,000,000	10/03/2022
New class - code to be confirmed	Unlisted Options (\$0.16,10 March 2024)	5,000,000	10/03/2022

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

NEUROTECH INTERNATIONAL LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ABN

Registration number

73610205402

1.3 ASX issuer code

NTI

1.4 The announcement is

☒ New announcement

1.5 Date of this announcement

10/3/2022



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

☒ Other

Please specify

The securities in the Appendix 3B dated 3 March 2022 have not been provided with a security code

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

☒ does not have an existing ASX security code ("new class")



Part 3C - number and type of +securities the subject of this notification (new class) where issue has not previously been notified to ASX in an Appendix 3B

New +securities**ASX +security code**

New class - code to be confirmed

+Security description

Unlisted Options (\$0.08, 10 March 2024)

+Security type

Options

ISIN code**Date the +securities the subject of this notification were issued**

10/3/2022

Will all the +securities issued in this class rank equally in all respects from their issue date?☒ Yes**Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?**☒ No**Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.**

Subject to vesting conditions, the Options will be exercisable at \$0.08 and expire two years from their date of issue. The Options will vest 12 months after the commencement date of Dr Andrews as CEO, subject to Dr Andrews remaining continually employed by the Company on this date.

Refer to the ASX release dated 3 March 2022 for further information.

Options Details

+Security currency

AUD - Australian Dollar

Exercise price

AUD 0.08000000

Expiry date

10/3/2024

Details of the existing class of +security that will be issued upon exercise or conversion of this new class of company option

Other

Description

Unlisted Options (\$0.08, 10 March 2024)

Any other information the entity wishes to provide about the +securities the subject of this notification

N/A



Please provide any further information needed to understand the circumstances in which you are notifying the issue of these +securities to ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

The securities were proposed to be issued in the Appendix 3B dated 3 March 2022 however the securities have not been provided with a security class code to date.

Issue details

Number of +securities

5,000,000

Were the +securities issued for a cash consideration?

☒ No

Please describe the consideration being provided for the +securities

The Company has issued 5,000,000 options to CEO, Alexandra Andrews, as the first tranche of the equity based component to her remuneration package.

Purpose of the issue

Other

Additional Details

The securities form the equity based component to the CEO's remuneration package.

New +securities

ASX +security code

New class - code to be confirmed

+Security description

Unlisted Options (\$0.12, 10 March 2024)

+Security type

Options

ISIN code

Date the +securities the subject of this notification were issued

10/3/2022

Will all the +securities issued in this class rank equally in all respects from their issue date?

☒ Yes

Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?

☒ No



Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.

Subject to vesting conditions, the Options will be exercisable at \$0.12 and expire two years from their date of issue. The Options will vest 18 months after the commencement date of Dr Andrews as CEO, subject to Dr Andrews remaining continually employed by the Company on this date.
Refer to the ASX release dated 3 March 2022 for further information.

Options Details

+Security currency	Exercise price	Expiry date
AUD - Australian Dollar	AUD 0.12000000	10/3/2024

Details of the existing class of +security that will be issued upon exercise or conversion of this new class of company option

Other

Description

Unlisted Options (\$0.12, 10 March 2024)

Any other information the entity wishes to provide about the +securities the subject of this notification

N/A

Please provide any further information needed to understand the circumstances in which you are notifying the issue of these +securities to ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

The securities were proposed to be issued in the Appendix 3B dated 3 March 2022 however the securities have not been provided with a security class code to date.

Issue details

Number of +securities

5,000,000

Were the +securities issued for a cash consideration?☒ No**Please describe the consideration being provided for the +securities**

The Company has issued 5,000,000 options to CEO, Alexandra Andrews, as the second tranche of the equity based component to her remuneration package.

Purpose of the issue

Other

Additional Details

The securities form the equity based component to the CEO's remuneration package.

New +securities**ASX +security code**

New class - code to be confirmed

+Security description

Unlisted Options (\$0.16, 10 March 2024)

+Security type

Options

ISIN code**Date the +securities the subject of this notification were issued**

10/3/2022

Will all the +securities issued in this class rank equally in all respects from their issue date?☒ Yes**Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?**☒ No**Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.**

Subject to vesting conditions, the Options will be exercisable at \$0.16 and expire two years from their date of issue. The Options will vest 24 months after the commencement date of Dr Andrews as CEO, subject to Dr Andrews remaining continually employed by the Company on this date.
Refer to the ASX release dated 3 March 2022 for further information.



Options Details

+Security currency	Exercise price	Expiry date
AUD - Australian Dollar	AUD 0.16000000	10/3/2024

Details of the existing class of +security that will be issued upon exercise or conversion of this new class of company option

Other

Description

Unlisted Options (\$0.16, 10 March 2024)

Any other information the entity wishes to provide about the +securities the subject of this notification

N/A

Please provide any further information needed to understand the circumstances in which you are notifying the issue of these +securities to ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

The securities were proposed to be issued in the Appendix 3B dated 3 March 2022 however the securities have not been provided with a security class code to date.

Issue details

Number of +securities

5,000,000

Were the +securities issued for a cash consideration?☒ No**Please describe the consideration being provided for the +securities**

The Company has issued 5,000,000 options to CEO, Alexandra Andrews, as the third tranche of the equity based component to her remuneration package.

Purpose of the issue

Other

Additional Details

The securities form the equity based component to the CEO's remuneration package.





Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:

(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +Securities (Total number of each +class of +securities quoted)

ASX +security code and description	Total number of +securities on issue
NTI : ORDINARY FULLY PAID	697,699,126

4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
NTIAP : OPTION EXPIRING 22-DEC-2022 EX \$0.03	6,620,000
NTIAM : OPTION EXPIRING 30-NOV-2023 EX \$0.038	4,000,000
NTIAN : OPTION EXPIRING 31-OCT-2023 EX \$0.015	10,000,000
NTIAO : OPTION EXPIRING 31-OCT-2023 EX \$0.02	10,000,000
NTIAS : PERFORMANCE RIGHTS	15,000,000
NTIAD : OPTION EXPIRING 18-NOV-2022 EX 1.89C	10,000,000
NTIAE : OPTION EXPIRING 18-NOV-2024 EX 5.89C	6,500,000
NTIAF : OPTION EXPIRING 18-NOV-2024 EX 1.99C	5,429,754
NTIAK : OPTION EXPIRING 31-JAN-2023 EX 0.5C	16,590,356
NTIAL : OPTION EXPIRING 31-JAN-2023 EX \$0.01	33,000,000
NTIAR : OPTION EXPIRING 12-MAY-2023 EX \$0.09	11,000,000
New class - code to be confirmed : Unlisted Options (\$0.08, 10 March 2024)	5,000,000
New class - code to be confirmed : Unlisted Options (\$0.12, 10 March 2024)	5,000,000



New class - code to be confirmed : Unlisted Options (\$0.16,10 March 2024)

5,000,000



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

☒ No

5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

☒ No

5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

☒ Yes

5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

15,000,000 Options.

5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

☒ No